Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of MK-0653C in Japanese Patients with Hypercholesterolemia
NCT02460159Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Jun 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ezetimibe and atorvastatin in hypercholesterolemia and heterozygous familial hypercholesterolemia (HeFH) (2 arms), sponsored by Organon & Co. Primary endpoints: Percentage of Participants Who Experience 1 or More Adverse Event (AE) at 54 weeks, Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs at 54 weeks and 2 more. Started Jun 2015; status: completed.
02
Drugs
ezetimibeatorvastatin
03
Conditions
hypercholesterolemiaheterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT02460159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460159.